| Bioactivity | AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation[1][2]. | ||||||
| Name | AMY-101 TFA | ||||||
| CAS | 1789738-04-0 | ||||||
| Shortening | YICV-{Trp(Me)}-QDW-{Sar}-AHRC-{N(Me)Ile}-NH2 (Disulfide bridge:Cys3-Cys13) | ||||||
| Formula | C83H117N23O18S2.xC2HF3O2 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture and light
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
AMY-101 TFA
CAS: 1789738-04-0 F: C83H117N23O18S2.xC2HF3O2 W:
AMY-101 TFA (Cp40 TFA), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally oc
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.